You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Zika viral pseudoinfectious virus as Zika vaccine candidate

    SBC: Tengen Biomedical Co            Topic: NIAID

    Executive Summary of Predicate SBIR/STTR Phase I Grant and Team TenGen Biomedical Co. and Howard University received an STTR Phase I grant (5R41AI129119-02) from the National Institute of Allergy and Infectious Diseases (NIAID) in 2017. The overall objective of our predicate STTR Phase I grant is to develop a safe, effective, and affordable Zika vaccine based on the novel concept of the third gene ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting lipid rafts for treatment of migraine

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NINDS

    PROJECT SUMMARY Migraine is a highly prevalent condition with an extraordinarily negative impact on quality of life and represents a heavy socioeconomic burden to the societyprimarily because of decreased working efficiency and workdays lostManagement of migraine has become increasingly pharmacological during recent yearsWhile several therapeutic options existmost of the prophylactic drugs current ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Novel monoclonal antibody for single dose treatment of acute CNS injury

    SBC: Oncosynergy, Inc.            Topic: 999

    PROJECT SUMMARY Traumatic brain injury (TBI) represents a significant societal and economic impact. To date, there are no FDA- approved pharmacotherapies to prevent or reverse TBI. The standard of care in an emergency setting focuses first on stabilizing the patient and secondly on management of cerebral hemodynamics. The patient may undergo surgery to remove hematomas, repair skull fractures, and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Selective inhibitors of Heme Transporters as Antiparasitic Agents

    SBC: RAKTA THERAPEUTICS INC            Topic: NIAID

    DESCRIPTION provided by applicant Neglected Tropical Diseases NTD which include helminthiasis and leishmaniasis are a group of thirteen parasitic and bacterial infections that affect over billion people Although these are devastating diseases of global concern their neglected status relative to other health concerns has resulted in a limited arsenal of therapeutic compounds for their ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS

    SBC: NOVORON BIOSCIENCE INC            Topic: NINDS

    7. Project Summary Multiple sclerosis (MS) is a neurodegenerative disease in which myelin of the central nervous system (CNS) is destroyed by a self-reactive immune response. This demyelination is accompanied by the death of the myelinating cells themselves, the oligodendrocytes. Repeated bouts of demyelination leave the denuded CNS neurons vulnerable to degradation and is the major cause of neuro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Optimizing HaploSeq for whole-genome phased haplotypes in biomedical applications

    SBC: ARIMA GENOMICS, INC.            Topic: 172

    DESCRIPTION provided by applicant Phenomenal advances in DNA sequencing technologies have enabled systematic identification of genetic variants in human individuals and the recent FDA marketing authorization of the first next generation genome sequencer signals the arrival of a new era of pharmacogenomics and personalized medicine Nevertheless DNA sequencing alone fails to provide complete i ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel, Microscale, Distributable Sensor Technology for Ionizing Radiation

    SBC: CFD RESEARCH CORPORATION            Topic: DTRA14B004

    Terrorist use of radioactive nuclear materials via nuclear and/or radiological dispersion devices (dirty bombs) is a serious threat. Therefore, it is crucial to detect proliferation of nuclear material. Critical challenges include: (a) high sensitivity detection of signature emissions from radioactive isotopes, and (b) cost-effectiveness for deployment of sensor networks across large storage facil ...

    STTR Phase II 2019 Department of DefenseDefense Threat Reduction Agency
  8. A Percutaneous Ultrasound-Guided Catheter for Organ and Vascular Access

    SBC: PERCEPTIVE NAVIGATION LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Safe and reliable access to major blood vessels and internal organs will be beneficial to patients with cardiovascular disease and cancer An interventional catheter with forward viewing ultrasound imaging capability will be developed to enable image guided access to blood vessels and internal organs Phase experiments demonstrate feasibility of building a hi ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Novel therapy for Fragile X syndrome

    SBC: Epigen Biosciences, Inc.            Topic: 101

    PROJECT SUMMARY Fragile X syndromeFXSis the most common inheritable form of cognitive impairment and the leading known genetic cause of autismFXS is caused by the loss of expression of the fragile X mental retardation proteinFMRPA major challenge for FXS research is to develop treatment strategies that improve the intellectual capabilities of patientsDysregulated protein synthesis is widely accept ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette users

    SBC: AUTOMATE SCIENTIFIC, INC.            Topic: NIDA

    Abstract E cigarettes (E-cigs) are increasingly popular worldwide, in particular, among youths. E-cigs may contribute to nicotine addiction and are unlikely to discourage conventional cigarette smoking. Mainstream and second-hand E-cig aerosols contain, in addition to nicotine, detectable levels of toxins including carcinogens and heavy metals such as formaldehyde, benzene, nitrosamines, cadmium a ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government